Table 3

Intensification of major second-line therapies in subcohort 2 (N = 278,188)

GLP-1RAINSTZDDPP-4iSUAll
N11,43136,33728,84146,822149,109278,188
Follow-up from second ADD initiation, years*3.85 (2.24)3.56 (2.09)5.40 (2.66)3.37 (1.81)4.09 (2.35)4.02 (2.33)
Initiated third ADD, n (% of N)5,942 (52)10,677 (29)18,788 (65)23,840 (51)81,980 (55)144,106
Initiated INS, n (% of N)3,285 (29)8,223 (29)9,633 (21)45,293 (30)67,812
Restricted mean time to a third ADD, years§4.23 (4.14, 4.32)6.15 (6.09, 6.21)3.53 (3.49, 3.58)4.12 (4.07, 4.17)3.91 (3.88, 3.93)4.18 (4.17, 4.20)
Restricted mean time to INS, years§6.58 (6.49, 6.67)6.82 (6.78, 6.87)7.14 (7.09, 7.18)6.26 (6.23, 6.28)6.51 (6.49, 6.53)
Added third ADD
n1 (% of N)4,522 (40)9,675 (27)12,481 (43)18,881 (40)73,776 (49)121,559 (44)
 HbA1c, %*8.2 (1.7)8.9 (2)8.1 (1.8)8.5 (1.8)8.6 (1.7)8.5 (1.8)
 HbA1c, mmol/mol667465697069
 HbA1c ≥7.5% (58 mmol/mol), n (% of n1)1,798 (61)4,953 (74)4,102 (55)8,968 (69)32,611 (72)53,100 (69)
 HbA1c ≥8% (64 mmol/mol), n (% of n1)1,364 (47)4,160 (62)3,101 (42)6,974 (54)26,231 (58)42,330 (55)
 GLP-1RA as third ADD, n (% of n1)2,125 (22)1,532 (12)1,643 (9)5,662 (8)11,230 (9)
 INS as third ADD, n (% of n1)2,356 (52)3,338 (27)5,472 (29)20,483 (28)32,447 (27)
 TZD as third ADD, n (% of n1)241 (5)688 (7)1,425 (8)19,010 (26)21,472 (18)
 DPP-4i as third ADD, n (% of n1)481 (11)2,488 (26)3,804 (30)25,216 (34)32,696 (27)
 SU as third ADD, n (% of n1)865 (19)3,090 (32)3,048 (24)7,556 (40)14,844 (12)
 SGLT2i as third ADD, n (% of n1)521 (12)938 (10)138 (1)2,399 (13)2,077 (3)6,095 (5)
Switched to third ADD
n2 (% of N)1,420 (12)1,002 (3)6,307 (22)4,959 (11)8,204 (6)22,547 (8)
 HbA1c, %*7.9 (1.6)8.2 (1.8)7.8 (1.7)8.1 (1.7)8.7 (2)8.2 (1.8)
 HbA1c, mmol/mol636662657266
 HbA1c ≥7.5% (58 mmol/mol), n (% of n2)470 (54)377 (60)1,846 (49)1,940 (59)3,380 (68)8,231 (59)
 HbA1c ≥8% (64 mmol/mol), n (% of n2)335 (38)280 (44)1,290 (34)1,451 (44)2,780 (56)6,286 (45)
 GLP-1RA as third ADD, n (% of n2)84 (8)383 (6)842 (17)677 (8)2,065 (9)
 INS as third ADD, n (% of n2)262 (18)703 (11)849 (17)4,012 (49)5,931 (26)
 TZD as third ADD, n (% of n2)61 (4)48 (5)273 (6)510 (6)924 (4)
 DPP-4i as third ADD, n (% of n2)488 (34)269 (27)2,199 (35)2,436 (30)5,561 (25)
 SU as third ADD, n (% of n2)390 (27)521 (52)2,829 (45)2,456 (50)6,450 (29)
 SGLT2i as third ADD, n (% of n2)205 (14)66 (7)109 (2)464 (9)373 (5)1,228 (5)
  • n1, number of subcohort 2 patients for each drug class who added a third ADD; n2, number of subcohort 2 patients for each drug class who switched to a third ADD. *Mean (SD);

  • †mean;

  • §mean (95% CI).

  • ‡Subcohort 2: those with MET as first-line treatment, who initiated second ADD, with a minimum of 1 year of follow-up post–second drug initiation.